| Literature DB >> 31161035 |
Joung Ha Park1, Seung Hee Ryu2, Jeong Young Lee2, Hyeon Jeong Kim2, Sun Hee Kwak2, Jiwon Jung1,2, Jina Lee3, Heungsup Sung4, Sung-Han Kim1,2.
Abstract
Background: Invasive aspergillosis (IA) is an opportunistic fungal infection that mostly occurs in immunocompromised patients, such as those having hematologic malignancy or receiving hematopoietic stem cell transplantation. Inhalation of Aspergillus spores is the main transmission route of IA in immunocompromised patients. Construction work in hospitals is a risk factor for environmental fungal contamination. We measured airborne fungal contamination and the incidence of IA among immunocompromised patients, and evaluated their correlation with different types of construction works.Entities:
Keywords: Construction; Fungal spore; Invasive aspergillosis
Mesh:
Year: 2019 PMID: 31161035 PMCID: PMC6542016 DOI: 10.1186/s13756-019-0543-1
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Clinical characteristics of patients with invasive aspergillosis at the time of IA diagnosis
| Period 1a ( | Period 2b ( | |
|---|---|---|
| Age, median years (IQR) | 44 (17–60) | 59 (43–63) |
| Male gender, no. (%) | 10 (59) | 11 (73) |
| Underlying hematologic disease, no. (%) | ||
| Acute myeloid leukemia | 8 (47) | 5 (33) |
| Acute lymphoid leukemia | 1 (6) | 2 (13) |
| Myelodysplastic syndrome | 3 (18) | 0 (0) |
| Lymphoma | 2 (12) | 1 (7) |
| Othersc | 3 (18) | 7 (47) |
| Immunocompromised condition | ||
| Neutropeniad | 12 (80) | 11 (79) |
| Hematopoietic stem cell transplant | 6 (40) | 5 (36) |
| Steroid usee | 3 (20) | 3 (21) |
| T-cell immunosuppressant | 2 (13) | 3 (21) |
| Human immunodeficiency virus infection | 1/15f (7) | 0/12f (0) |
| Symptoms at the time of IA diagnosis | ||
| Fever | 13 (87) | 11 (79) |
| Cough | 4 (27) | 4 (29) |
| Sputum | 2 (13) | 4 (29) |
| Dyspnea | 6 (40) | 3 (21) |
| Positive results for serum galactomannan | 9 (53) | 12 (80) |
| Positive results for beta-D-glucan | 8/14f (57) | 9/12f (75) |
| Positive results for culture specimens | 4 (24) | 4 (27) |
| Hospitalization days before IA diagnosis, median days (IQR) | 23.0 (9.0–58.0) | 43.5 (12.8–86.3) |
| Antifungal prophylaxis | ||
| Micafungin | 2 (13) | 1 (7) |
| Posaconazole | 1 (7) | 2 (14) |
| Fluconazole | 2 (13) | 2 (14) |
| No antifungal prophylaxis | 10 (67) | 9 (64) |
| Antifungal agentg | ||
| Voriconazole | 11 (65) | 11 (73) |
| Amphotericin B | 5 (29) | 1 (7) |
| Echinocandin | 1 (6) | 1 (7) |
| Others | 0 (0) | 2 (13) |
| 30-day mortality | 5 (29) | 3 (20) |
IQR interquartile range
aFrom September 2017 – October 2017, during demolition and excavation works
bFrom November 2017 – February 2018, during framing, interior designing, plumbing, and finishing works
c1 chronic myeloid leukemia, 6 aplastic anemia, 1 multiple myeloma, 1 hemophagocytic lymphohistiocytosis, 1 neuroblastoma
dAbsolute neutrophil count < 500/mm3 for more than 10 days
e > 0.3 mg/kg/day prednisolone for more than 3 weeks
fExcluded patients who did not undergo appropriate tests
gAntifungal agent that was used for the treatment of current invasive aspergillosis for over 75% of the total duration
Fig. 1Airborne fungal spore levels in three hematologic wards during a 6 month construction period. CFU, colony-forming unit
Fig. 2Incidence of invasive aspergillosis in three hematologic wards during a 6 month constructionperiod. *Incidence: number of cases per 1000 person-days. IA, invasive aspergillosis. *Incidence: number of cases per 1000 person-days. a7,934 person-days during period 1. b15,050 person-days during period 2